Products Categories
CAS No.: | 81093-37-0 |
---|---|
Name: | Pravastatin |
Article Data: | 17 |
Molecular Structure: | |
Formula: | C23H36O7 |
Molecular Weight: | 424.535 |
Synonyms: | 1-Naphthaleneheptanoicacid, 1,2,6,7,8,8a-hexahydro-b,d,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-,[1S-[1a(bS*,dS*),2a,6a,8b(R*),8aa]]-;3b-Hydroxycompactin;Eptastatin;Mevalothin;Pravastatin acid;1-Naphthaleneheptanoicacid, 1,2,6,7,8,8a-hexahydro-b,d,6-trihydroxy-2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-,(bR,dR,1S,2S,6S,8S,8aR)-; |
Density: | 1.21g/cm3 |
Melting Point: | 171.2-173 °C |
Boiling Point: | 634.5 °C at 760 mmHg |
Flash Point: | 213.2 °C |
Appearance: | Off-white Cryst. |
Hazard Symbols: | F, C |
Risk Codes: | 11-34 |
Safety: | 16-26-36/37/39-45 |
PSA: | 127.12000 |
LogP: | 1.10570 |
1. Introduction of Pravastatin
Pravastatin is one kind of white powder or white to yellowish white powder or crystalline powder, odorless, bitter taste. The IUPAC Name of this chemical is (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-Hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid. Besides, its Classification Code is Anticholesteremic agents; Antilipemic Agents; Antimetabolites; Enzyme Inhibitors; Hydroxymethylglutaryl-CoA reductase inhibitors. In addition, Pravastatin water solubility is 2464mg/L.
2. Properties of Pravastatin
Physical properties about Pravastatin are:
(1)Melting point: 171.2-173 °C; (2)Index of Refraction: 1.554; (3)Molar Refractivity: 111.98 cm3; (4)Molar Volume: 349.1 cm3; (5)Surface Tension: 53.9 dyne/cm; (6)Density: 1.21 g/cm3; (7)Flash Point: 213.2 °C; (8)Enthalpy of Vaporization: 107.45 kJ/mol; (9)Boiling Point: 634.5 °C at 760 mmHg; (10)Vapour Pressure: 9.15E-19 mmHg at 25°C; (11)XLogP3: 1.6; (12)H-Bond Donor: 4; (13)H-Bond Acceptor: 7; (14)Rotatable Bond Count: 11; (15)Exact Mass: 424.246103; (16)MonoIsotopic Mass: 424.246103; (17)Topological Polar Surface Area: 124; (18)Heavy Atom Count: 30; (19)Formal Charge: 0; (20)Complexity: 656; (21)Isotope Atom Count: 0; (22)Defined Atom Stereocenter Count: 8; (23)Undefined Atom Stereocenter Count: 0; (24)Defined Bond Stereocenter Count: 0; (25)Undefined Bond Stereocenter Count: 0; (26)Covalently-Bonded Unit Count: 1; (27)Feature 3D Acceptor Count: 6; (28)Feature 3D Donor Count: 3; (29)Feature 3D Anion Count: 1; (30)Feature 3D Hydrophobe Count: 2; (31)Feature 3D Ring Count: 2; (32)Effective Rotor Count: 12; (33)Conformer Sampling RMSD: 1.
3. Structure Descriptors of Pravastatin
(1)InChI: InChI=1S/C23H36O7/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28)/t13-,14-,16+,17+,18+,19-,20-,22-/m0/s1
(2)InChIKey: TUZYXOIXSAXUGO-PZAWKZKUSA-N
(3)Canonical SMILES: CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC(CC(CC(=O)O)O)O)O
(4)Isomeric SMILES: CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O
(5)Smiles: C1=2C=C[C@H](C)[C@@H]([C@H]1[C@H](C[C@@H](O)C2)OC([C@H](CC)C)=O)CC[C@H](C[C@H](CC(O)=O)O)O
4. Safety information of Pravastatin
Hazard Codes of Pravastatin (81093-37-0): F,C
Risk Statements: 11-34
R11:Highly flammable.
R34:Causes burns.
Safety Statements: 16-26-36/37/39-45
S16:Keep away from sources of ignition.
S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
S36/37/39:Wear suitable protective clothing, gloves and eye/face protection.
S45:In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
5. Uses of Pravastatin
Pravastatin (81093-37-0) is commonly used for lowering blood pressure, cholesterol drugs. As a reductase inhibitor, for a variety of models have reduced the role of hyperlipidemia, for lowering blood pressure, cholesterol, from the micro-organisms to be hydroxide. Pravastatin is one of the lower potency statins; but its increased hydrophilicity is thought to confer advantages such as minimal penetration through lipophilic membranes of peripheral cells, increased selectivity for hepatic tissues, and a reduction in side effects compared with lovastatin and simvastatin.